Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry the May 10 2022 spoofing episode was a permanent reversal of the SP trend. The 7 market makers should have their trading license revoked.
Your full of poop.
Let us have some learning guys talking about the lawsuit this weekend.
⚾️SWING AND A MISS: Market Maker(s) & Hedge Fund(s) failure to properly set up their scapegoat, Adam Feuerstein⚾️$NWBO filed a lawsuit against seven market makers accusing them of illegally spoofing NWBO’s stock. Spoofing is a way to illegally manipulate a stock price either up… pic.twitter.com/ij7xbI2ReN
— hoffmann6383 (@hoffmann6383) May 3, 2024
Yeah, probably happening more often than we think.
Here's a wacky hypothesis. It used to be you can only have 6 or 7 posters on ignore at 1 time then sometime in the last couple of years I was able to put a ton of posters on ignore at 1 time to my hearts content which I did. Maybe too many posters on ignore are causing an anomaly in the system just like in the Matrix (which I just rewatched).
On my kindle, I use my left thumb to scroll up. That's where the ignore button is. I have accidentally ignored some posters here while reading their messages.
Sorry,
I will have to apologize for my concern about not having Flipper or anyone else on ignore.
I was not aware where the ignore button was and must have accidentally put Flipper on ignore.
On the phone it is easy to accidentally toggle because it is on the bottom where one might hold the phone.
Thanks Mike and Guzzi, IHub.
I am relieved to find this was the problem:)
2B
dr_low or Inquirig,
Thanks for all your psychic predictions. I see that you’re back to being a legal expert again too. You can calm down a little bit—why so many frantic posts and reposts all day everyday? 😶
We will get our news and information from sources that are reliable and fact-based ✅️
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-moves-from-optimization-of-flaskworks-prototype-to-fabrication-of-gmp-compliant-units-for-installation-validation-and-final-testing-prior-to-regulatory-certification-302054769.html
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173720548
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173771995
Defendants’ Allege NWBO Failed to Plead Loss Causation Under the Temporal Proximity Theory
“The SAC should be dismissed because it does not allege spoofing close enough in time to the close on any “Pricing Date” used to determine NWBO’s sale price. “
“In an efficient market, the alleged spoofing would cause mispricing for seconds at most, not the hours or days NWBO claims."
"No court has ever found spoofing’s impact lasts more than seconds, let alone an hour."
Ah yes! Merck, NCI, and Oncovir were all listed as collaborators on the ongoing UCLA study prior to 2024!
I stand corrected. ✅️
⭐️Combo is King! ⭐️
https://classic.clinicaltrials.gov/ct2/show/NCT04201873
https://www.oncovir.com/pipeline1
https://www.laweekly.com/oncovir-inc-is-pushing-the-boundaries-of-medical-innovation-with-hiltonol/
Doesn't change the fact that LP is gonna bring NWBO down another 99%
Oncovir was added as a sponsor to the combo trial back in 2020.
Nobody wants to ask why NWBO is not a sponsor?
Best of luck with the scan.You are so right about the process for approval!
Ah. Some, people, pay attention to the “Fudsters”. Just sayin, lol. … (In fact, some, people, could put the good DD on ignore, and just watch the “Fudsters”.
AANS2024 Chicago
Monday, May 6, 2024
11:06 AM – 11:26 AM CT
Location: S503ab
Linda Liau – Immunotherapy.
Congratulations to the stellar lineup of UCLA #Neurosurgery Faculty & Residents who are scheduled at the @AANSNeuro Annual Meeting this weekend! Schedule: https://t.co/y6CRiQe2fi@ausaf @geoffreycolbymd @SpineNeuro @inspired_brain @IsaacYangMD @ShivaniBaisi_MD @brainbro #AANS2024 pic.twitter.com/oQ8oHKHmyz
— UCLA Neurosurgery 🧠 (@UCLANsgy) May 1, 2024
No one is paying attention to you anymore. Too many lies and distortions. For too long.
The 700K to 1M share number is the number of shares in all markets that were not delivered in T-2 window. That is a tiny fraction of all shares traded.
For NWBO, the numbers showed 300 FTD shares on 4/1 and 5,046 shares on 4/9. In both cases all were delivered by the next day.
Anybody who thinks that is some huge issue is snorting coke.
https://www.sec.gov/data/foiadocsfailsdatahtm
JAMA Oncology was a milestone, and now all eyes are on cell-based combination therapy too! This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment. https://t.co/Uso7Pkh1Kt
⭐️Combo is King!⭐️
https://www.uclahealth.org/departments/neurosurgery/ucla-neurosurgery-aans-2024-annual-meeting
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-dr-linda-liau-has-joined-the-companys-scientific-advisory-board-301924864.html
https://www.jci.org/articles/view/169314
https://www.fda.gov/drugs/our-perspective/50-years-progress-treating-patients-cancer
https://clinicaltrials.gov/study/NCT04201873
https://www.uclahealth.org/news/article/fda-approval-brain-cancer-alzheimers
The ignore option is a lovely thing, especially once you have a take on who's useful to read and who's noise.
More of the same remarkably widespread manipulation behavior as identified by:
Devin Nunes: “We knew it was bad but we finally got the numbers this week, and the first two weeks of April, there was 700,000 to 1 million shares a day that aren’t covering […] Now, what we’ve done was an investigation […] and now we’ve identified companies that are likely… pic.twitter.com/oBlH8a7cVJ
— alphastate 🇺🇸 (@alpha5tate) May 4, 2024
Disciples say...Just pretend it didn't happen and there'll still be a certain percentage of retail dimwits out there to serve us.
It's interesting that Dr. Liau is not yet speaking about what happens when DCVax-L is combined with other therapeutics. I believe the reason is based on the formalities applied to clinical trials in which nobody speaks officially about advancements until they've in some way been presented for peer review. Let's hope that happens in the near future.
To my way of thinking the entire process of developing new products takes entirely to long. While a company can release a TLD statement, it's very general, just an overall impression of what they've seen, and as we know the peer review can take a year or more before either Journal, or acceptance at a proper conference occurs. How many lives could be saved if the regulators really got into what was seen in a trial and if justified did an EUA to make the product available while all the formalities of peer review and formal filing for approval, often in excess of a million pages, is done over what's often in excess of a year.
It's not that no data has been revealed from the trials at UCLA, interim results are spectacular, but in a formal presentation by Dr. Liau, she's apparently not discussing them. I feel certain that if she were treating a patient with DCVax-L they would also be receiving Poly-ICLC. I don't know if the company is permitting her to treat such patients if they're not officially in a UCLA trial, though she clearly knows how to make the vaccine herself.
Yesterday I saw a neurologist because of essential tremor, which is hereditary as my father had it. While she doesn't suspect anything, she's having me do a brain scan, which I've never had previously. While I've been very pleased with City of Hope, if there we a problem requiring surgery, I'd probably try to go with UCLA and Dr. Liau if possible, only because of the after surgery treatment that may be available there, and nowhere else, at least right now.
If the EUA were used more frequently, I would suspect the regulators would have had sufficient evidence to do so back at the point where the trial was resumed after the halt. I believe the German's insisted that all get the vaccine because they clearly saw the benefits, and the others did come over to their way of thinking. I suppose the other aspect of using an EUA would be having a production facility that wasn't fully approved for commercial production, but was qualified to supply pivotal quality trial material. How many tens or hundreds of thousands of patients might have been benefitted if an EUA had been done back then?
Gary
oh, WONDERING . . . . . . when i read the first words, i'd expect ImmunityBio!? Never thought its LWLG. Total different industry. . . . but quite the same huge impact, huge perspective, extraordinary success for companies and investors!
Absolutely. It can happen. We’ve seen it happen. But I don’t count on markets to operate normally at these levels. In fact, I count on them NOT to operate as they are supposed to in order to find unusual opportunities. We know shorts and MM’s scratch each other’s backs and so too do some writers in this space get involved in that nonsense. Success with a deep financial meaning is the ultimate validator. Sometimes it had to have immediate meaning or shorts are going to play with longs to get as much of the value for themselves as they can.
Krisgo, glad you took the time to listen to Dr Liau. In the trial 13% had 5 year or better survival. She spoke of the mgmt methylated had 20% 5 year survival and that is typical of most studies in that the mgmt methylated live longer than those that are not. Dr Liau has said in many other presentations that this vaccine works for some but only for a % of patients. It is one more tool to help with this disease but more is still needed. As temozolomide in trials added about 3 months to survival and is now part of soc and dcvax in this trial also added about 3 months to median survival then imo should be approved as an added treatment. Best thing is that for some % it results in long term survival - 13% for the study group as a whole and better for the mgmt methylated- obviously less so for those that are not mgmt methylated. Thanks for listening to her talk. Some here just criticize anything that doesn't say dcvax cures everything and do not even listen to the many presentations from Liau and Prins and others. I prefer to deal whith the factual data as presented by the dedicated researchers
I don't know if anyone knew the size of the trade, anyone see it?
Gary
How big was that trade ? If it was few hundred or few thousand shares , it is a fluke and incosequential
I am still curious about the after-hours trade on Thursday. If the trader does have some information, it would have been normal to believe it would be released on Friday. The company, on the other hand, should know that good news is best released early in the business week and does have the flexibility to do so.
If there is anything to this Monday, it should be very interesting.
Gary
The National Health Service of Britain just told you that, hopefully, cancer vaccines will be available in around five years, and you all ignore it. LOL x10
>>The NHS has said it HOPES cancer vaccines will be available to thousands of patients in the UK within the next FIVE years,
Roman,
Great post!
The value is only for cancer. I put a multiplier on your number if I want to include the fields like antiviral, antibacteria, antifungus, autoimmune diseases.
You didn't see the presentation about the Moonshot in which the colorectal cancer and the brain tumor were specifically mentioned, did you?
You can laugh for now. Don't forget. I'll have the last laugh.
Truthfan,
Did you notice what Battelle was doing with the $149m fund? It was something related to small peptide, Liquid Chromatography with Tandem Mass Spectrometry, and enzyme-linked immunospot (ELISPOT) assay, which makes me have fantasy.
https://www.battelle.org/insights/newsroom/press-release-details/battelle-amplifybio-andelyn-biosciences-win-research-contract-for-national-institute-of-neurological-disorders-and-stroke
https://govtribe.com/award/federal-idv-award/indefinite-delivery-contract-75n95022d00021
I’ve not had you on ignore at any point. I bounce on and off using my ignore list feature. It speeds reading to have it on, but occasionally I check post titles when it is off. I’ll try turning it off when I anticipate not being on the board.
How long have you been roaming on this board? 12 years?
I don't mean to brag. But holding this ticker for about three years, I know a lot better than you. I think the reason could be you are hired by someone so you have no motivation to study hard and dig deeper.
Ned,
Now you know the colorectal trial is real, don't you?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174356517
Be prepared that RevImmune most likely could have a bunch of secret trials.
Roman.......
Thanks for sharing that info
Is there a button to ignore the management of NWBO because apparently it's a default setting!!!!!
Clown
Yes, LL says she hopes -L can be made available while further trials advance. But what exactly does that mean?
48:00 She talks about how hopefully in the future patients can get access to treatment while trials continue for proving or disproving efficacy. Goes on to talk of hopefully allowing patient right to try for -L.
That she talks about -L being used via RTT sounds like she has doubts on any near FDA approval.
35:50 Talking about SAP LL notes "and you are aware of the limitations of using external control populations"
42:20 Asked about trial design (ECA) limitations. LL notes that to "mitigate some of the limitations using external controls" they used MAIC to make up for the lack of patient level data in the ECA. She notes "so we are not able to do individual patient level matching which we are all aware is a current limitation of the use of external controls". She goes on to talk of how hopefully the discussion around this trial will put pressure for changes to make patient level data more available.
The patient level data issue is huge. There is a reason why the FDA says in their ECA guidance that patient level data is required. The attempts to get around this limitation have serious issues. MAIC is questionable even if it had all the key data, which did not exist in this case. There assertion the trials were matched is comical. 2 were genetic subgroups and none required for intent for near total resection. Most all allowed biopsies.
On some less significant points:
41:40 LL talks about how the unique immune status if the CNS is a rational for -L.
That is a rational theory as to why a DC vaccine might work better for GBM than other tumors. But if true, then the arguments that DCvax shoudl work in all cancers loses support.
36:50 LL talks about how the crosover arm was added in order to get patients to enroll.
It really does not matter why the crossover arm was added, but some here assert it was required by the FDA. Certainly LL has made contradictory statements on this, but both the SAP and LP have said it was per NWBO to help enrollment.
Thank God I bought 87 million shares at 13 cents... said every moron on this board.
LOL
I would bet that there is not ONE single profitable investor in this stock! NOT ONE!
"You are a better man than I, Gunga Din!"
I guess I could wade through the neck deep crap that gets posted here, too, but I think I already have a sense of the vibe of this board. There seems to be a core of folks who try to share information here. And an army of termites, trying to take it down.
There is a setting in your profile to ignore responses to ignored posters. Upper right corner of the screen.
I got tired of reading people defending against posts from the dirtbags I was ignoring.
Thanks. I'll check out.
Can’t agree more… keep building that moat LP!!!
Doc usually needs a week to reply to the tough ones.
Thank you for the reply!!
It is amazing to see how many of the long term NWBO shareholders (myself included) are also investors in LWLG! I think there has been a good bit of cross-pollination....
Speaking of combo rj found this update L/keytruda/poly
Hoping for an update on the #DCVax-L Poly-ICLC Keytruda Combo Trial:
— rj (@sharpie510) May 4, 2024
🤞https://t.co/L69FJCgipA
Note: the Study Record was UPDATED on 05/01/24.
👏$nwbo #glioblastoma #gbm $mrk $bmy $rhhby
Here's what Dr. Nghiemphu said about the combo trial 2 years ago:https://t.co/9BG3C30KOD
Followers
|
1621
|
Posters
|
|
Posts (Today)
|
100
|
Posts (Total)
|
689011
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |